João H Duarte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1046391/publications.pdf Version: 2024-02-01



IOÃEO H DUARTE

#	Article	IF	CITATIONS
1	Fate mapping of IL-17-producing T cells in inflammatory responses. Nature Immunology, 2011, 12, 255-263.	7.0	1,031
2	The Aryl Hydrocarbon Receptor: Multitasking in the Immune System. Annual Review of Immunology, 2014, 32, 403-432.	9.5	708
3	Plasticity of TH17 cells in Peyer's patches is responsible for the induction of T cell–dependent IgA responses. Nature Immunology, 2013, 14, 372-379.	7.0	429
4	Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions. Immunity, 2014, 40, 989-1001.	6.6	285
5	Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. European Journal of Immunology, 2009, 39, 948-955.	1.6	221
6	External influences on the immune system via activation of the aryl hydrocarbon receptor. Seminars in Immunology, 2011, 23, 99-105.	2.7	150
7	IL-22 Fate Reporter Reveals Origin and Control of IL-22 Production in Homeostasis and Infection. Journal of Immunology, 2014, 193, 4602-4613.	0.4	115
8	Differential Influences of the Aryl Hydrocarbon Receptor on Th17 Mediated Responses in vitro and in vivo. PLoS ONE, 2013, 8, e79819.	1.1	102
9	Regulation and function of innate and adaptive interleukinâ€17â€producing cells. EMBO Reports, 2012, 13, 113-120.	2.0	71
10	The aryl hydrocarbon receptor: fine-tuning the immune-response. Current Opinion in Immunology, 2010, 22, 747-752.	2.4	57
11	The Transcription Factor E4BP4 Is Not Required for Extramedullary Pathways of NK Cell Development. Journal of Immunology, 2014, 192, 2677-2688.	0.4	51
12	Autophagy prevents age-related OA. Nature Reviews Rheumatology, 2015, 11, 683-683.	3.5	27
13	CD8 T Cells and IFN-Î ³ Emerge as Critical Players for Psoriasis in a Novel Model of Mouse Psoriasiform Skin Inflammation. Journal of Investigative Dermatology, 2013, 133, 871-874.	0.3	19
14	Cutting Edge: Intrathymic Differentiation of Adaptive Foxp3+ Regulatory T Cells upon Peripheral Proinflammatory Immunization. Journal of Immunology, 2010, 185, 3829-3833.	0.4	18
15	Inflammation feeds inflammation—HDAC5 downregulation leads to activation of fibroblast-like synoviocytes in RA. Nature Reviews Rheumatology, 2015, 11, 64-64.	3.5	16
16	SIRT6 prevents chondrocyte senescence and DNA damage. Nature Reviews Rheumatology, 2015, 11, 260-260.	3.5	11
17	Large intergenic noncoding RNA linked to disease activity and organ damage in SLE. Nature Reviews Rheumatology, 2015, 11, 384-384.	3.5	8
18	Alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption. Nature Reviews Rheumatology, 2014, 10, 446-446.	3.5	4

JOãO H DUARTE

#	Article	IF	CITATIONS
19	mTORC is a potential therapeutic target in APS. Nature Reviews Nephrology, 2014, 10, 544-544.	4.1	3
20	mTORC is a potential therapeutic target in APS. Nature Reviews Rheumatology, 2014, 10, 513-513.	3.5	3
21	Vagal stimulation in patients with HF. Nature Reviews Cardiology, 2014, 11, 621-621.	6.1	3
22	Fullerene nanoparticles ameliorate disease in arthritis mouse model. Nature Reviews Rheumatology, 2015, 11, 319-319.	3.5	3
23	ICOS sustains pathogenic T-cell survival in SLE mouse model. Nature Reviews Rheumatology, 2015, 11, 260-260.	3.5	3
24	IRF5 mediates joint inflammation. Nature Reviews Rheumatology, 2015, 11, 562-562.	3.5	3
25	Cholesterol efflux capacity—a new biomarker for cardiovascular risk?. Nature Reviews Cardiology, 2015, 12, 2-2.	6.1	3
26	Osteoclasts and ACPAs — the joint link. Nature Reviews Rheumatology, 2016, 12, 69-69.	3.5	3
27	Colchicine therapy prevents postpericardiotomy syndrome but not postoperative atrial fibrillation. Nature Reviews Cardiology, 2014, 11, 620-620.	6.1	2
28	Long-term iron therapy is beneficial in patients with HF. Nature Reviews Cardiology, 2014, 11, 622-622.	6.1	2
29	Cost-effectiveness of 2014 guidelines. Nature Reviews Cardiology, 2015, 12, 194-194.	6.1	2
30	Hitting the brakes on ectopic lymphoid structure formation. Nature Reviews Rheumatology, 2015, 11, 621-621.	3.5	2
31	Impaired mucosal immunity in patients with SLE. Nature Reviews Rheumatology, 2014, 10, 637-637.	3.5	1
32	Targeted delivery of packaged siRNA promotes osteogenesis. Nature Reviews Rheumatology, 2015, 11, 196-196.	3.5	1
33	Mesenchymal stromal cell therapy improves myocardial function after severe ischaemic heart failure. Nature Reviews Cardiology, 2015, 12, 382-382.	6.1	1
34	Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism. Nature Reviews Cardiology, 2015, 12, 66-66.	6.1	1
35	Neutrophil extracellular traps—a mechanism of thrombosis in patients with antiphospholipid syndrome?. Nature Reviews Rheumatology, 2015, 11, 444-444.	3.5	1
36	Alzheimer disease and dyslipidaemia. Nature Reviews Cardiology, 2015, 12, 318-318.	6.1	1

JOãO H DUARTE

#	Article	IF	CITATIONS
37	Drug-eluting stents or CABG?. Nature Reviews Cardiology, 2015, 12, 259-259.	6.1	1
38	Folic acid reduces stroke risk. Nature Reviews Cardiology, 2015, 12, 257-257.	6.1	1
39	New fusion protein reduces IL-1-mediated inflammation. Nature Reviews Rheumatology, 2015, 11, 503-503.	3.5	1
40	Antigen presentation by B cells contributes to murine lupus. Nature Reviews Rheumatology, 2015, 11, 564-564.	3.5	1
41	Risk of major coronary events not reduced by darapladib therapy. Nature Reviews Cardiology, 2014, 11, 621-621.	6.1	Ο
42	Deficient antigen-specific T cell responses in SLE-prone mice. Nature Reviews Rheumatology, 2014, 10, 700-700.	3.5	0
43	Fractional flow reserve-guided management of CAD. Nature Reviews Cardiology, 2014, 11, 619-619.	6.1	0
44	High-potency statins associated with increased diabetes risk. Nature Reviews Cardiology, 2014, 11, 435-435.	6.1	0
45	Altered antibody response to vaccination in patients with SLE. Nature Reviews Rheumatology, 2015, 11, 382-382.	3.5	Ο
46	HSCT—resetting immune tolerance by boosting TREG cell diversity. Nature Reviews Rheumatology, 2015, 11, 681-681.	3.5	0
47	Durable-polymer drug-eluting stents might not lead to very late stent thrombosis. Nature Reviews Cardiology, 2015, 12, 3-3.	6.1	Ο
48	CVD risk prevention—40-year programme improves outcomes. Nature Reviews Cardiology, 2015, 12, 132-132.	6.1	0
49	Migraine improvement after AF ablation. Nature Reviews Cardiology, 2015, 12, 195-195.	6.1	0
50	Secukinumab improves symptoms of psoriatic arthritis. Nature Reviews Rheumatology, 2015, 11, 503-503.	3.5	0
51	CAD genetic risk helps predict SCD. Nature Reviews Cardiology, 2015, 12, 380-380.	6.1	Ο